新诊断KMT2A重排急性髓系白血病的特征与结局
该研究分析了1611例急性髓系白血病(AML)患者,其中4.3%存在KMT2A重排。强化化疗(IT)联合维奈克拉的完全缓解/完全缓解伴血细胞计数不完全恢复(CR/CRi)率达100%,而低强度治疗(LIT)联合维奈克拉为61%;IT组5年总生存(OS)率和无事件生存(EFS)率分别为66%和64%,LIT组为7%。LIT组中N/KRAS突变对OS和EFS有预测作用。
要点
- KMT2A重排AML中信号相关基因突变常见:NRAS 30%、KRAS 23%、FLT3-TKD 16%。
- IT联合维奈克拉CR/CRi率100%,LIT联合维奈克拉61%。
- IT组5年OS率66%、EFS率64%,LIT组均为7%。
核心结论
- KMT2A重排AML患者接受IT的结局逐年改善,而接受LIT者生存仍差,凸显需要新型联合方案。
研究设计与样本
- 分析1611例AML患者,其中4.3%存在KMT2A重排。
主要发现
- 信号相关基因突变频率:NRAS 30%、KRAS 23%、FLT3-TKD 16%。
- IT组CR/CRi率81%,联合维奈克拉后升至100%;LIT组CR/CRi率33%,联合维奈克拉后为61%。
- IT组5年OS率66%、EFS率64%,LIT组均为7%。
- 39例(57%)在达到CR/CRi后接受异基因干细胞移植。
- LIT组多因素分析显示N/KRAS突变对OS有预测作用(HR 2.93,95%CI 1.18-7.29,P=0.021),对EFS有预测作用(HR 3.51,95%CI 1.35-9.24,P=0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) with KMT2A rearrangement (KMT2Ar) has poor outcomes. We analyzed 1,611 patients with AML and 4.3% demonstrated rearrangements in KMT2A. Signaling-related genes (NRAS 30%, KRAS 23% and FLT3-TKD 16%) were the most frequently mutated in patients with KMT2Ar AML. Patients treated with intensive chemotherapy (IT) achieved a complete remission (CR)/CR with incomplete blood count recovery (CRi) rate of 81%, and when combined with venetoclax, the CR/CRi rate increased to 100%. Patients treated with low intensity treatment (LIT) achieved an CR/CRi rate of 33%, and when combined with venetoclax, the CR/CRi rate was 61%. For patients treated with IT, the 5-year overall survival (OS) and event-free survival (EFS) rates were 66% and 64%, respectively, compared with 7% in those treated with LIT. Thirty-nine patients (57%) underwent allogeneic stem cell transplantation after achieving CR/CRi. For patients treated with LIT, multivariate analysis demonstrated that N/KRAS mutations were predictive for OS (HR 2.93, 95% CI 1.18-7.29, P = 0.021) and EFS (HR 3.51, 95% CI 1.35-9.24, P = 0.01). In summary, outcomes in KMT2Ar AML have improved over years in patients treated with IT, whereas those treated with LIT continue to show poor survival, highlighting the need for novel combinations.
引用
- Bataller A, Goulart HE, Issa GC, et al. Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements. Leukemia. 2025. PMID: 40346311. doi:10.1038/s41375-025-02634-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。